Differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma and squamous cell carcinoma

  • Zhilei Cui Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Linlin Zhang Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Lin Song Department of Respiratory Medicine, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Keywords: non-small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma, inflammation, cisplatin


Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent type of cancer worldwide and associated with high mortality rate. An effective treatment for NSCLC is urgently needed. This study aimed to investigate differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), thereby providing insights into the mechanisms underlying inflammation in NSCLC.

Materials and methods: The resistance of A549 and SK-MES-1 cells to cisplatin treatment was determined by IC50. The migration and invasion capacity of A549 and SK-MES-1 cells was determined using migration and invasion assay kits. The apoptosis rate was evaluated. The protein expression levels of caspase-3 and Ki67 were measured by western blot. ELISA assay was used to determine the levels of inflammatory cytokines, including IL-4, IL-6, IL-8, and TNF-α.

Results: Patients with LUAD showed shorter survival than LUSC patients after the chemotherapy treatment. LUAD was more resistant to cisplatin treatment, corresponding with a higher IC50 observed in A549 cells than SK-MES-1 cells. Moreover, A549 cells showed higher migration and invasion capacity and lower apoptosis rate than SK-MES-1 cells. In addition, SK-MES-1 LUAD samples showed stronger inflammation response than LUAD samples and A549 cells. Accordingly, inflammation cytokines promoted the migration and invasion of SK-MES-1 cells, whereas inhibited cell apoptosis.

Conclusions: The present study suggests that LUAD is more resistant to chemotherapy and shows a stronger inflammation response than LUSC. Inflammatory cytokines could enhance the resistance of LUAD to chemotherapy and further promote tumor cell proliferation, migration, and invasion.


Download data is not yet available.


John U, Hanke M. Lung cancer mortality and years of potential life lost among males and females over six decades in a country with high smoking prevalence: an observational study. BMC Cancer 2015; 15: 876. doi: 10.1186/s12885-015-1807-7

Visser S, de Mol M, Cheung K, van Toor JJ, van Walree NC, Stricker BH, et al. Treatment satisfaction of patients with advanced non-small-cell lung cancer receiving platinum-based chemotherapy: results from a prospective cohort study (PERSONAL). Clin Lung Cancer 2018; 19(4): e503–16. doi: 10.1016/j.cllc.2018.03.003

Circu M, Cardelli J, Barr MP, O’Byrne K, Mills G, El-Osta H. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One 2017; 12(9): e0184922. doi: 10.1371/journal.pone.0184922

Saha B, Kodys K, Szabo G. Hepatitis C virus-induced monocyte differentiation into polarized M2 macrophages promotes stellate cell activation via TGF-beta. Cell Mol Gastroenterol Hepatol 2016; 2(3): 302–16.e8. doi: 10.1016/j.jcmgh.2015.12.005

Yu J-S, Jin J, Li Y-Y. The physiological functions of IKK-selective substrate identification and their critical roles in diseases. STEMedicine 2020; 1(4): e49. doi: 10.37175/stemedicine.v1i4.49

de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13: 118–37. doi: 10.1159/000092969

Chang WS, Wang SC, Chuang CL, Ji HX, Hsiao CL, Hsu CM, et al. Contribution of interleukin-4 genotypes to lung cancer risk in Taiwan. Anticancer Res 2015; 35(11): 6297–301.

Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang W, et al. Activation of the IL-4/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells. Front Immunol 2019; 10: 2638. doi: 10.3389/fimmu.2019.02638

Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188(6): 1039–46. doi: 10.1084/jem.188.6.1039

Seebauer CT, Brunner S, Glockzin G, Piso P, Ruemmele P, Schlitt HJ, et al. Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells. Oncoimmunology 2016; 5(12): e1242543. doi: 10.1080/2162402X.2016.1242543

Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, et al. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One 2017; 12(7): e0181125. doi: 10.1371/journal.pone.0181125

Zheng T, Ma G, Tang M, Li Z, Xu R. IL-8 secreted from M2 macrophages promoted prostate tumorigenesis via STAT3/MALAT1 pathway. Int J Mol Sci 2018; 20(1): 98. doi: 10.3390/ijms20010098

Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM. TNF-α and IL-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 2003; 38(3): 117–23. doi: 10.1002/mc.10151

Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The role of tumor inflammatory microenvironment in lung cancer. Front Pharmacol 2021; 12: 688625. doi: 10.3389/fphar.2021.688625

Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008; 43(3): 374–9. doi: 10.1016/j.cyto.2008.07.014

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454(7203): 436–44. doi: 10.1038/nature07205

Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008; 267(2): 204–15. doi: 10.1016/j.canlet.2008.03.028

Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev 2008; 11(1): 1–15. doi: 10.1080/10937400701436460

Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013; 82(2): 179–89. doi: 10.1016/j.lungcan.2013.07.025

Ning Y, Hui N, Qing B, Zhuo Y, Sun W, Du Y, et al. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation. Cell Death Dis 2019; 10(6): 414. doi: 10.1038/s41419-019-1635-9

Li L, Yin JY, He FZ, Huang MS, Zhu T, Gao YF, et al. Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget 2017; 8(57): 97476–89. doi: 10.18632/oncotarget.22138

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15(11): e493–503. doi: 10.1016/S1470-2045(14)70263-3

Zhang H, Han K. High intensity focused ultrasound enhances anti-tumor immunity through promoting CD4 Th1 effector T cell response. STEMedicine 2020; 1(4): e65. doi: 10.37175/stemedicine.v1i4.65

Jia D, Li L, Andrew S, Allan D, Li X, Lee J, et al. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis 2017; 8(7): e2932. doi: 10.1038/cddis.2017.319

Murata M. Inflammation and cancer. Environ Health Prev Med 2018; 23(1): 50. doi: 10.1186/s12199-018-0740-1

Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res 2007; 67(3): 871–5. doi: 10.1158/0008-5472.CAN-06-3641

Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67(11): 1516–23. doi: 10.1136/ard.2008.092932

Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013; 31(6): e69–72. doi: 10.1200/JCO.2012.44.2020

Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013; 15(4): 210. doi: 10.1186/bcr3436

Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 2011; 6(11): e27621. doi: 10.1371/journal.pone.0027621

Singh RK, Lokeshwar BL. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res 2011; 71(9): 3268–77. doi: 10.1158/0008-5472.CAN-10-2769

How to Cite
CuiZ., ZhangL., & SongL. (2022). Differences of inflammatory microenvironment and sensitive correlation to cisplatin-chemotherapy in lung adenocarcinoma and squamous cell carcinoma. STEMedicine, 3(4), e151. https://doi.org/10.37175/stemedicine.v3i4.151
Research articles